Printer Friendly

Novo Nordisk and Pharmacia reach out-of-court settlement in human growth hormone.

Novo Nordisk A/S (Denmark; 45-4442-4137) announced an out-of-court settlement in a US patent infringement lawsuit brought against Pharmacia Corporation (Bedminster, NJ). The suit involved Genotropin (somatropin (rDNA origin) for injection), Pharmacia's biosynthetic human growth hormone product which competes with Novo Nordisk's Norditropin (somatropin (rDNA origin) for injection) human growth hormone.

The agreement will have no significant impact on Novo Nordisk's financial results. Terms of the settlement will not be disclosed.

Lars Rebien Sorensen, president and CEO of Novo Nordisk said, "We are pleased to have reached an equitable settlement with Pharmacia regarding this litigation. We have thus achieved our goal of protecting our intellectual property without adversely affecting the well-being of patients."

The Novo Nordisk growth hormone, Norditropin, was first introduced in Europe in 1988, and was later approved by the US Food and Drug Administration in 1995. Norditropin cartridge and NordiPen, the first and only premixed growth hormone for a pen, was introduced into the US market in October 2000.

Novo Nordisk is a focused healthcare company and the world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as coagulation disorders, growth disorders and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society.

Novo Nordisk employs approximately 14,000 people in 68 countries and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London.
COPYRIGHT 2000 Biotech Patent News
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2000 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:patent dispute; Novo Nordisk A/S and Pharmacia Corp.
Comment:Novo Nordisk and Pharmacia reach out-of-court settlement in human growth hormone.(patent dispute; Novo Nordisk A/S and Pharmacia Corp.)
Publication:BIOTECH Patent News
Article Type:Brief Article
Geographic Code:1USA
Date:Nov 1, 2000
Previous Article:Antigenics wins crucial patent battle with Stressgen.
Next Article:Avitar receives approval on Oralscreen collector patent.

Related Articles
Novo Nordisk sues Sanofi-Aventis for insulin delivery device patent infringement.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters